Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TT001
- Development stage
- Unknown
- Lead developer
- Ting Therapeutics
- Modality
- Small Molecules
01
Overview
TT001 is a small molecule drug developed by Ting Therapeutics for the prevention of hearing loss, particularly as an otoprotective agent during cisplatin-based chemotherapy. Its mechanism of action is as a cyclin-dependent kinase 2 (CDK2) inhibitor, aiming to protect against cisplatin-induced ototoxicity without interfering with the anti-cancer efficacy of cisplatin. The drug is in early clinical development (Early Phase 1) and has been supported by NIH funding for preclinical and early clinical studies focused on pharmacokinetics, pharmacodynamics, and safety in animal models. Ting Therapeutics holds exclusive international rights for CDK2 inhibitors in hearing loss treatment[1][2][4].
02
Targets
CDK2 (Cyclin-dependent kinase 2)
Beyond the preview
Go deeper on TT001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TT001.